Does asthma phenotype have impact on disease control

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-004905-15-DK

Enrollment

Registered

2014-01-22

Start date

2014-01-22

Completion date

Unknown

Last updated

2016-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma MedDRA version: 16.1 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

Interventions

Trade Name: Bricanyl Pharmaceutical Form: Inhalation powder INN or Proposed INN: TERBUTALINE CAS Number: 23031-25-6 Concentration unit: 1X 100 milligrams/millilitre Concentration type: equal Concentra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Asthmatics with positiv mannitol age 18-80 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 45 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 45

Exclusion criteria

Exclusion criteria: Other pulmonary disease

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the impact of asthma phenotype and disease control;Secondary Objective: Do patients receive a faster improvement in asthma control when controlled by NO measurement;Primary end point(s): Improvement of Airway hyperresponsiveness to Mannitol;Timepoint(s) of evaluation of this end point: 2 years from first patient	—

Secondary

Measure	Time frame
Secondary end point(s): Proving improvement of asthma when controlled by NO;Timepoint(s) of evaluation of this end point: 2 years	—

Countries

Denmark

Contacts

Public ContactRespiratory Research Unit

Respiratory Research Unit, Bispebjerg Hospital

a.homoee@gmail.com

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026